Wkw Seto
University of Hong Kong
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Wkw Seto.
Alimentary Pharmacology & Therapeutics | 2018
Lung-Yi Mak; Danny Ka-Ho Wong; Ks Cheung; Wkw Seto; Ching-Lung Lai; M.-F. Yuen
Chronic hepatitis B (CHB) cannot be completely eradicated due to the presence of covalently closed circular DNA (cccDNA) in the nuclei of infected hepatocytes. While quantification of intrahepatic cccDNA requires liver biopsies, serological markers can be non‐invasive alternatives to reflect intrahepatic viral replicative activity. Recently, hepatitis B core‐related antigen (HBcrAg) has been advocated as a novel serum marker for disease monitoring and prognostication of CHB.
Journal of Hepatology | 2011
Wkw Seto; Cl Lai; Jyy Fung; John Chi-Hang Yuen; Dkh Wong; M.-F. Yuen
This journal supplement is Abstract Book of the International Liver Congress 2011 by EASL (46th Annual Meeting)
Alimentary Pharmacology & Therapeutics | 2016
Wkw Seto; Jyy Fung; Ks Cheung; Lung-Yi Mak; R. Hui; Kevin Sze-Hang Liu; Ching-Lung Lai; M.-F. Yuen
Factors influencing changes in liver stiffness measurements during long‐term nucleoside analogue therapy for chronic hepatitis B (CHB) have not been thoroughly investigated.
Alimentary Pharmacology & Therapeutics | 2017
Wkw Seto; Eric H. Y. Lau; J.T. Wu; Ivan Fan-Ngai Hung; Wai K. Leung; Ks Cheung; Jyy Fung; Ching-Lung Lai; M.-F. Yuen
The temporal relationship between nucleoside analogue therapy for chronic hepatitis B (CHB) and liver cancer development has not been evaluated at a population level.
Clinical Microbiology and Infection | 2016
Danny Ka-Ho Wong; Jyy Fung; Cheuk-Kwong Lee; Wkw Seto; J. N. S. Leung; Fung-Yu Huang; Che-Kit Lin; Ching-Lung Lai; M.-F. Yuen
We studied the intrahepatic hepatitis B virus (HBV) replicative status in 40 people with occult hepatitis B infection (OBI) and 40 patients with chronic hepatitis B (CHB). Intrahepatic HBV DNA, covalently closed circular DNA (cccDNA), and pre-genomic RNA (pgRNA) were quantified. Patients with OBI had median necroinflammation and fibrosis scores of 1 and 0, respectively. Intrahepatic total HBV DNA, cccDNA and pgRNA were detectable in 30 (77%), one (3%) and five (13%) of the participants with OBI, respectively. People with OBI had lower median intrahepatic total HBV DNA than the patients with CHB (p < 0.0001). They had nearly normal liver histology and low intrahepatic HBV replication.
Journal of Hepatology | 2016
Shk Liu; Wkw Seto; Dkh Wong; John Chi-Hang Yuen; Yuk-Fai Lam; Ks Cheung; W.P.E. To; K.L.M. Ko; Lung-Yi Mak; Ching-Lung Lai; M.-F. Yuen
Poster Presentations: Viral hepatitis: Hepatitis A, B, D, E – clinical (except therapy): no. THU-162
Archive | 2012
Wkw Seto; Dkh Wong; Jyy Fung; Ppc Ip; Jch Yuen; Ifn Hung; Cl Lai; Rmf Yuen
The 22nd Conference of the Asian Pacific Association for the Study of the Liver APASL 2012—Taipei, Taiwan—16–19 February
Alimentary Pharmacology & Therapeutics | 2018
Grace Lai-Hung Wong; Wkw Seto; Vincent Wai-Sun Wong; M.-F. Yuen; Henry Lik-Yuen Chan
Safety profile of nucleos(t)ide analogues is an important issue in view of its widespread use for decades in patients with chronic hepatitis B (CHB).
Archive | 2014
Dkh Wong; Jyy Fung; Ck Lee; Wkw Seto; J Leung; Dkh Huang; Ck Lin; Cl Lai; Rmf Yuen
23rd Annual Conference of APASL March 12–15, 2014, Brisbane, Australia Asian Pacific Association for the Study of the Liver 2014 Topic: 1 Acute Liver Failure
Archive | 2011
Wkw Seto; Cl Lai; Jyy Fung; Jch Yuen; Dkh Wong; M.-F. Yuen
The 21st Conference of the Asian Pacific Association for the Study of the Liver
